Abstract: The standard chemotherapy for ovarian cancer is paclitaxel/carboplatin. Patients often exhibit myelosuppressive toxicity, and the treatment response varies considerably. In this study, we investigated the previously reported SNPs 1199G>A (rs2229109), 1236C>T (rs1128503), 2677G>T/A (rs2032582), 3435C>T (rs1045642) in ABCB1, and 1196A>G (rs10509681) in CYP2C8 and their association with treatment-induced myelosuppression, progression-free survival (PFS) and overall survival (OS). From the phase III study, OAS-07OVA, 525 patients (All) treated with carboplatin and paclitaxel administered as Paclical (Arm A, n = 260) or Taxol â (Arm B, n = 265) were included and genotyped using pyrosequencing. Genotype associations with myelosuppression, PFS and OS were investigated using ANOVA, Kaplan-Meier analysis and Cox proportional hazard models. The most prominent finding was for the ABCB1 variant 3435TT, which was significantly associated with increased PFS in All (hazard ratio (HR) = 0.623), in Arm A (HR = 0.590) and in Arm B (HR = 0.627), as well as increased OS in All (HR = 0.443) and in Arm A (HR = 0.372) compared to the wild-type, 3435CC. For toxicity, the most interesting finding concerned the haplotype, including 1236TT, 2677TT and 3435TT, which was associated with higher neutrophil values in Arm B (p = 0.039) and less neutrophil decrease in All (p = 0.048) and in Arm B (p = 0.021). It is noteworthy that the results varied depending on the treatment arm which indicates that the effects of ABCB1 variants vary with the treatment regimen. Our results reflect the contradictory results of previous studies, confirming that small variations in the composition of treatment regimens and patient populations may influence the interpretation of SNPs effects on treatment outcome.
Ovarian cancer is one of the leading causes of cancer-related deaths among women in Europe [1] . The standard chemotherapy for primary and recurrent ovarian cancer is paclitaxel in combination with carboplatin [2] [3] [4] . Patients initially respond well to this treatment, but the recurrence rate is around 70%, and the relative 5-year survival rate for stages III and IV is only 25-30% [5] . Myelosuppression is a common toxicity of paclitaxel and carboplatin therapy: neutrophil depression is the most acute haematological toxicity, but thrombocytopenia, leukopenia and neutropenia are all commonly acquired by patients undergoing the treatment [2, [6] [7] [8] [9] . Neuropathy is another, often dose-limiting, side effect of paclitaxel [2, 10, 11] .
Paclitaxel is insoluble in water, and the solvent Cremophor â EL (CrEL) is used in the traditional formulation of paclitaxel, Taxol â , to circumvent this [12] . However, the use of CrEL can lead to hypersensitivity reactions. Therefore, newer paclitaxel formulations that apply nanotechnology to form watersoluble micelles, such as Paclical and Abraxane â [12, 13] , have been developed. Currently, dosages are adapted to the body surface area and Calvert's formula for paclitaxel and carboplatin, respectively. However, there remains considerable variation in both treatment response and toxicities. There is a need for better means of individualization of the therapy. The interindividual differences in treatment response and toxicity are thought to be partly attributable to genetic differences.
The two proteins, ABCB1 and CYP2C8, are involved in the transportation and hepatic metabolism of paclitaxel, respectively [14] . ABCB1 expression affects paclitaxel resistance in ovarian cancer cell lines [15] and has for a long time been known to affect paclitaxel drug disposition [16] . CYP2C8 is the main metabolizing enzyme of paclitaxel, and genetic variations can alter this metabolism [17] . The effect of variations in these genes on treatment response and toxicity in cancers treated with paclitaxel has been extensively studied. However, the results, from both our group and others, have yielded inconclusive and contradictory results [6, 7, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , reviewed by Krens et al. [29] and Fredericks et al. [30] .
This inconsistency and the inability to replicate previously reported results for genetic variants in ABCB1 and CYP2C8 in relation to toxicity and response can partly be blamed on the use of small sample sizes, differences in treatment regimens, concomitant medications, the ethnicity of patients and the inclusion of various cancer types. This study was designed to evaluate and validate the association between the SNPs ABCB1 1199G>A (rs2229109), 1236C>T (rs1128503), 2677G>T/A (rs2032582), 3435C>T (rs1045642), CYP2C8 1196A>G (rs10509681) and paclitaxel/carboplatin-induced myelosuppression, progression-free survival (PFS) and overall survival (OS) in 525 ovarian cancer patients homogeneously treated with paclitaxel and carboplatin.
Materials and Methods
Study population. This study was conducted using a subset of patients from the phase III study OAS-07OVA (EudraCT -2008-002668-32, ClinicalTrials.gov -NCT00989131). This phase III study included 789 patients with recurrent ovarian cancer with the intent to compare the efficacy and safety of paclitaxel micellar nanoparticles, Paclical, with paclitaxel CrEL, Taxol â . Eligible patients were randomized to treatment Arm A consisting of Paclical (250 mg/m 2 , given as a 1-hr IV infusion) and carboplatin (AUC 5-6) repeated every three weeks for six cycles; or treatment Arm B consisting of Taxol â (175 mg/m 2 , given as a 3-hr IV infusion) and carboplatin (AUC 5-6) repeated every three weeks for six cycles. A total of 525 patients (All; Arm A n = 260 and Arm B n = 265) were included in this pharmacogenetics study after giving written informed consent, following the Helsinki Declaration and with permission from the regional ethics committees. Peripheral blood samples were collected and stored at À80°C prior to DNA extraction.
Myelosuppression. Blood status was measured at baseline; at days 1, 8 and 15 through cycles 1 and 2; at days 1 and 8 through cycles 3-6; and at the end of the study. Myelosuppression was evaluated for thrombocytes, leucocytes and neutrophils as nadir values during the first cycle and during the whole treatment. The nadir values were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The relative decreases in values from the baseline were also evaluated during the first cycle and during the whole treatment, according to Equation 1.
Relative decrease ¼ ðbaseline value À nadir valueÞ baseline value ð1Þ
Progression-free survival and overall survival. Progression-free survival (PFS) and overall survival (OS) were measured as the time from inclusion to an event, that is confirmed progression with computed tomography (CT) or death for PFS and OS, respectively. CT scans were performed within 6 weeks before treatment, after cycles 3 and 6, every third month during the follow-up period, and when the patient left the study.
DNA extraction and genotyping. DNA was extracted from blood samples using the Promega Maxwell 16 system (Promega Biotech, Nacka, Sweden) according to the manufacturer's protocol. Genotyping of 1199G>A, 1236C>T, 2677G>T/A, and 3435C>T in ABCB1 and 1196A>G in CYP2C8 was performed using the pyrosequencer PSQ96MD (Qiagen, Uppsala, Sweden) according to the manufacturer's protocol, as previously described [20, 22] . In short, HotStar Taq Master Mixture (VWR International, Stockholm, Sweden) was used for polymerase chain reaction (PCR) amplification performed on a Mastercycler gradient (Eppendorf, Hamburg, Germany) with the total volume 10 lL using 0.4 lmol/L primer, 1.5 mmol/L MgCl 2 and annealing temperature of 58°C. Sequencing primer and biotinylated single-stranded PCR template were annealed at 80°C for 2 min., enzyme and substrate were added, and sequencing was carried out by dispensing dNTPs in a predefined order.
ABCB1 haplotype. The haplotype structure of ABCB1 has previously been described by Kroetz et al. [31] . In this study, haplotypes involving the variants 1236C>T, 2677G>T (excluding the low frequency A variant) and 3435C>T in ABCB1 were investigated. Haplotypes were formed for all patients that were homozygous wildtype, heterozygous or homozygous variant at all three variant positions, denoted as CCGGCC, CTGTCT, and TTTTTT (in order of physical appearance, i.e. 1236C>T, 2677G>T, 3435C>T) in the remainder of this article.
Statistical analysis. Patient characteristics, baseline blood values and genotype frequencies were compared between the treatment arms using logistic regression or ANOVA. Accordance of genotype distributions with the Hardy-Weinberg equilibrium and the Caucasian population in dbSNP was also evaluated. Common Terminology Criteria for Adverse Events grades of thrombocytes, leucocytes and neutrophils were compared between the treatment arms using Fisher's exact test.
The association of baseline thrombocyte, leucocyte and neutrophil values with the patient characteristics treatment arm (A or B), age, relapse (first or second), Eastern Cooperative Oncology Group (ECOG) performance status, radiotherapy, cytoreductive surgery, previous treatment with paclitaxel/docetaxel and chemotherapy-free interval (≥1 or <1 year, defined as the time from last chemotherapy course to inclusion in this study) all relevant at the time of inclusion (tumour type and tumour stage were evaluated at primary diagnosis and had likely changed since; therefore, they were not investigated) were evaluated using ANOVA. The genotype association with nadir values and relative decreases in thrombocytes, leucocytes and neutrophils (during both the first cycle and the whole treatment) were assessed using ANOVA with the respective baseline values (only for nadir values, not for relative decreases) and treatment arm as covariables.
Kaplan-Meier analysis with the log-rank test was used to estimate differences in PFS and OS between genotypes. For genotypes found to be significant in the Kaplan-Meier analysis, Cox proportional hazard models were constructed using the covariables treatment arm, age, relapse, ECOG performance status, radiotherapy, cytoreductive surgery, previous treatment with paclitaxel/docetaxel, chemotherapy-free interval and dose delay/reduction (reduced or delayed dose administration during treatment). Patients with no registered event (progression or death) were censored at the date of their last CT scan or last follow-up for PFS and OS, respectively.
IBM SPSS Statistics version (v.) 23 was used for logistic regressions and Cox proportional hazard models. The statistical software R [32] 
Results
Patient characteristics and baseline blood status. Patient characteristics are presented in table 1. Logistic regression showed no significant differences (p > 0.05 for all comparisons) in patient characteristics between the treatment arms, and there were no significant differences between the treatment arms in terms of baseline blood values. Furthermore, ANOVA revealed an association between patient characteristics and baseline blood status (Table S1 ). However, these associations varied depending on blood cell types. All patients were of Caucasian ethnicity, except one who was of African descent. Although all the included patients were previously treated with platinum-containing chemotherapy, at least six months had passed, so they were deemed to be platinum-sensitive. A clinical paper comparing the treatment arms using the full study population of the phase III study OAS-07OVA is under preparation.
Genotyping and genotype distribution. Genotyping was successful, and genotype frequencies are summarized in Table S2 . There was no difference in genotype distributions between the treatment arms (p > 0.05 for all comparisons using logistic regression). The distribution of genotypes corresponded to the distribution seen for the Caucasian population in dbSNP (data not shown) and was in accordance with the Hardy-Weinberg distribution (data not shown).
The haplotype analysis of ABCB1 categorized 73, 169 and 89 patients as CCGGCC, CTGTCT and TTTTTT, respectively. This analysis excluded 294 patients who could not be classified into these haplotypes.
Toxicity.
Common Terminology Criteria for Adverse Events grades for nadir values (first cycle and whole treatment) for thrombocytes, leucocytes and neutrophils are shown in Table S3 . Fisher's exact test showed significantly higher/greater toxicity in treatment Arm A for all phenotypes (p < 0.05 for all comparisons). Inherent to the more prevalent toxicity in Arm A, 49 patients received dose delays/reductions before the second treatment cycle whereas only 23 patients in Arm B required this. Furthermore, during the whole treatment 170 patients in Arm A and 137 in Arm B required dose delays/reductions.
Results from the ANOVAs of 3435C>T, the haplotype and myelosuppression are shown in table 2. In summary, the variant alleles of 3435C>T and the haplotype were mainly associated with lower toxicity (except in Arm A where the variant allele of 3435C>T was associated with increased neutrophil toxicity). The direction of the toxicity can be interpreted from boxplots in Figures . It should be noted that the covariable treatment Arm (A or B) was always significant (data not shown) in the ANOVAs of toxicity in All. This was expected due to the harsher treatment regime in Arm A. Also, the covariable baseline blood status was significant (data not shown) in all but one analysis (Arm A, leucocytes, p = 0.104). For toxicity associations with 1199G>A, 1236C>T, 2677G>T/A and 1196A>G, see Data S1 and Table S4 .
Progression-free survival. Kaplan-Meier analysis showed no initial differences in PFS between the two treatment arms (data not shown). Table 3 lists the results from the Kaplan-Meier analyses of PFS for 3435C>T and the haplotype. Kaplan-Meier curves are shown in Figure S4 , and mean PFS times in months for all genotypes are listed in Table S5 . Cox proportional hazard models for PFS are presented in table 4 . This showed that the mean PFS in All for patients with 3435TT was 10.8 months compared to 9.6 months in patients with 3435CC, hazard ratio (HR) = 0.623 (confidence interval (CI) = 0.464-0.835, p = 0.002). In Arm A, the mean PFS for patients with 3435TT was 11.6 months compared to 9.8 months in patients with 3435CC, HR = 0.590 (CI = 0.390-0.893, p = 0.013). In Arm B, the mean PFS for patients with 3435TT was 10.0 months compared to 9.3 months in patients with 3435CC, HR = 0.627 (CI = 0.409-0.960, p = 0.032). For patients in All with the haplotype TTTTTT, the mean PFS was 11.0 months compared to 9.9 months in patients with the haplotype CCGGCC, HR = 0.652 (CI = 0.452-0.940, p = 0.022). This was also indicated in Arm A (p = 0.057). For patients in Arm B with the heterozygous haplotype CTGTCT, the mean PFS was 10.6 months compared to 10.1 months in patients with the haplotype CCGGCC, HR = 0.625 (CI = 0.394-0.991, p = 0.046). Kaplan-Meier analyses of PFS for 1199G>A, 1236C>T, 2677G>T/A and 1196A>G are summarized in Data S1, Tables S5 and S6 , and Figure S5 (only 1236C>T).
Overall survival.
Kaplan-Meier analysis showed no initial differences in OS between the two treatment arms (data not shown). Results from the Kaplan-Meier analyses of OS for 3435C>T and the haplotype are listed in table 3 and shown in Figure S6 , and the mean OS times in days for all genotypes are presented in Table S5 . Cox proportional hazard models for OS are presented in table 5 . This showed that the mean OS in All for patients with 3435TT was 431 days compared to 374 days in patients with 3435CC, HR = 0.443 (CI = 0.264-0.746, p = 0.002). In Arm A, the mean OS for patients with 3435TT Table S5 . 1 Haplotype combining all homozygous wild-type (CCGGCC), heterozygous (CTGTCT) and homozygous variant (TTTTTT) at all three positions 1236C>T, 2677G>T and 3435C>T. Tables S5 and S6 , and Figure S7 (only 1236C>T and 2677G>T).
Depiction of significant associations. Figure 1 shows an overall view of the significant associations for the ABCB1 variants 1199G>A, 3435C>T and the haplotype, as well as the CYP2C8 variant 1196A>G.
Discussion
The major strengths of this study are its large and clearly defined population using homogenous treatment in two different regimens. A potential drawback of the study is that variations in genes involved in DNA repair, metabolism and transportation essential for carboplatin [25, 33, 34] were not investigated. Variation in those genes could also influence toxicity, PFS and OS. However, as patients in both treatment arms were treated with equal doses of carboplatin, the effects should be similar in both and not a major contributor to the differences seen, although their impact cannot be ruled out entirely. Also, no correction for multiple testing was carried out, which should be borne in mind when interpreting the results.
Toxicity.
For ABCB1, the variant alleles of 1236C>T, 2677G>T, 3435C>T and the variant haplotype TTTTTT were associated (continued) with less myelosuppressive toxicity in All and in Arm B. Although this was not consistent for all blood cell types or for the duration of the treatment, it indicates that the effects of ABCB1 SNPs on myelosuppression may differ depending on factors specific to different blood cell types. However, we did not see the same pattern in Arm A. At the same time, Arm A had more myelosuppressive toxicity overall, probably due to the higher concentration of paclitaxel. This indicates that the protective effect of the variant alleles shown in Arm B can be counteracted by a harsher treatment regimen like the one used in Arm A. Hoffmeyer et al. [35] have previously shown decreased mRNA expression for the variant allele of 3435C>T, followed by increased digoxin plasma concentrations. This is in accordance with the results of Wang et al. [36] which showed decreased expression and lowered mRNA stability, which were subsequently supported by the findings of Sissung et al. [26] describing increased neutropenia in patients carrying 3435C>T variant alleles. On the contrary, Baldissera et al.
[37] describe higher ABCB1 expression for 3435T allele carriers in hepatocellular carcinoma samples. Furthermore, cell populations in peripheral blood and bone marrow express ABCB1 [38] . The idea is that lowered expression of ABCB1 leads to decreased cellular clearance of paclitaxel, higher intracellular concentrations and thus more cell death and greater toxicity. This infers that a low expression of ABCB1 in tumour cells would be beneficial to the treatment of cancer, and high expression of ABCB1 in blood cells would be helpful for preventing toxicity. Our findings that ABCB1 variant alleles decrease myelosuppressive toxicity cannot be explained by the results of Hoffmeyer et al. [35] , Wang et al. [36] and Sissung et al. [26] . However, the expression of ABCB1 in different cell types and the effects of the genetic variants on gene expression and toxicity are not fully known.
The CYP2C8 variant 1196A>G was associated with higher leucocyte toxicity in Arm A. 1196A>G is included in the CYP2C8*3 haplotype and is in linkage with rs1113129 (D' = 1.0 evaluated using SNAP [39] ) in CYP2C8-HapC. Previous studies have associated CYP2C8-HapC [40] and CYP2C8*3 [18, 22] with decreased paclitaxel clearance and CYP2C8-HapC [7] with lower leucocyte and neutrophil values. This means that CYP2C8 variation could mediate an increased risk of paclitaxel/carboplatin-induced leukopenia.
Survival.
Chemotherapy-free interval ≥ 1 year was the biggest contributor to longer PFS and OS. This is understandable as a more aggressive cancer would result in a faster recurrence, and thus shorter chemotherapy-free interval, and a worse prognosis. When PFS and OS were investigated, 1236TT, 3435TT and the haplotype TTTTTT were associated with longer PFS, and 1236TT, 2677TT, 3435TT and the haplotype TTTTTT were associated with longer OS compared to wild-types. The most prominent finding was that 3435TT showed increased PFS in All, Arm A and Arm B as well as enhanced OS in All and Arm A. This adds up to an indication of overall better prognosis for patients being 3435TT. The meta-analysis of 4616 ovarian cancer patients by Johnatty et al. [23] marginally associated 1236TT (rs1128503) with improved OS and showed a tendency for a worse prognosis in patients with higher tumour expression of ABCB1. Also, ABCB1 2677T/A (allele carriers), and patients with 1236TT and 3435CC have been associated with longer PFS [24, 27] . However, the latter is not supported by our findings as we found the 3435TT variants to be beneficial. Furthermore, some studies using different treatment regimens have not seen any differences between genotypes and PFS or OS [19, 25] , which might be explained by the fact that the different treatment regimens in our study yielded different associations of genotypes for PFS and OS (and myelosuppression). The effects observed are small and likely not only dependent on the genotypes but also on treatment conditions. Another critical factor that could affect differences in survival is the tumour expression of ABCB1. High ABCB1 tumour expression has been associated with poor prognosis and chemotherapy resistance by Sun et al. [41] . This was further strengthened by the results of Hoffmeyer et al. [35] and Wang et al. [36] showing that 3435TT is associated with lower ABCB1 expression, which supports our findings of 3435TT being favourable for PFS and OS (unlike the association seen with toxicity, as previously discussed). However, Gao et al. [42] have suggested that an ABCB1-related survival difference in ovarian cancer patients is more likely to be an effect of whole body paclitaxel clearance variations rather than an effect of the variant on cancer cells. As we do not know about the somatic ABCB1 mutations or tumour expression of ABCB1 in our samples, it is impossible to draw definite conclusions.
Lastly, the previously shown short progression-free survival of patients with the ABCB1 variant 1199G>A [19, 21] was not seen in the presented study. One explanation for this could be the presence of different haplotypes in different study populations, yet another contributor to the inconclusive body of literature published concerning ABCB1 genetic variants and their importance for treatment effects.
Conclusion
Combining the results from myelosuppression, PFS and OS, the study indicates a toxicity protective effect of variant alleles in ABCB1, especially for the variant allele of 3435C>T. The effects of ABCB1 variants in this study, using a large homogeneous patient sample, are however small and varied with the Fig. 1 . Overall view of the significant associations in the study. All significant associations of the ABCB1 variants 1199G>A, 3435C>T and the haplotype 1 as well as the CYP2C8 SNP 1196A>G with thrombocytes, leucocytes, neutrophils, progression-free survival and overall survival for All, Arm A and Arm B. Green indicates that the variant was associated with an advantage (lower toxicity, longer PFS or longer OS), and orange indicates that the variant was associated with a disadvantage (higher toxicity, shorter PFS or shorter OS). *p < 0.05. ** p < 0.01. 1 Haplotype combining all homozygous wild-type (CCGGCC), heterozygous (CTGTCT) and homozygous variant (TTTTTT) at all three positions 1236C>T, 2677G>T and 3435C>T.
dose of paclitaxel. This currently limits the predictive value of ABCB1 genotyping before the start of paclitaxel treatment in clinical practice, based on our results. Our results are reflected in the contradictory results of previous studies [6, 7, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , confirming that small variations in the composition of treatment regimens, and the selection of patient populations could influence the interpretation of the SNP effect on treatment outcome. Furthermore, the investigated variants might need different consideration depending on whether the aim is to minimize toxicity or maximize the antitumour effect of the treatment. Therefore, more thorough investigations of paclitaxel treatments and genotypes are needed in combination with ABCB1 expression analysis, and PK/PD studies in vivo and in vitro using different cell types and both normal and tumour tissues to obtain a clear idea of how to implement ABCB1 variation into the individualization of treatment regimens containing paclitaxel. 
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Data S1. Supplemental results. Figure S1 . The figures show jittering of the nadir values during the first cycle for different genotypes (with significant p-values in the ANOVA displayed in table 2 and Table S4 )accompanied by boxplots, mean, and standard deviations (S.D.). Figure S2 . The figures show a jittering of the nadir values during the whole course of the treatment for different genotypes (with significant p-values in the ANOVA displayed in table 2 and Table S4 ) accompanied by boxplots, mean, and standard deviations (S.D.). in table 2 and Table S4 ) accompanied by boxplots, mean, and standard deviations (S.D.). Figure S4 . Kaplan-Meier curves for progression-free survival (PFS), in months, for 3435C>T and the haplotype in All, Arm A and Arm B. Significance was assessed using the log-rank test. Figure S5 . Shows Kaplan-Meier curves for progression-free survival (PFS), in months, for 1236C>T in All, Arm A and Arm B. Significance was assessed using the log-rank test. Figure S6 . Kaplan-Meier curves for overall survival (OS), in days, for 3435C>T and the haplotype in All, Arm A and Arm B. Significance was assessed using the log-rank test. Figure S7 . Shows Kaplan-Meier curves for overall survival (OS), in days, for the 1236C>T and 2677C>T genotypes in All, Arm A and Arm B. Significance was assessed using the log-rank test. Table S1 . Baseline ANOVA. Table S2 . Genotyping results. Table S3 . Patient toxicity. Table S4 . Toxicity ANOVA. Table S5 . Mean PFS and OS times. Table S6 . PFS and OS p-values from Kaplan-Meier analysis.
